Navigation Links
Rensselaer Polytechnic Institute wins $2.45 million grant to support stem cell research

Troy, N.Y. Rensselaer Polytechnic Institute and principal investigator Glenn Monastersky have been awarded a four-year $2.45 million grant from the New York Stem Cell Science Program (NYSTEM) of the Empire State Stem Cell Board.

Monastersky, director of operations at the Center for Biotechnology and Interdisciplinary Studies (CBIS), said the grant will be used to create an upstate center of excellence for basic stem cell research within the CBIS.

"The funds awarded today by New York state will be used to build out sophisticated laboratories with high-throughput culture and imaging equipment in the CBIS, dedicated to the very specialized needs of stem cell researchers," Monastersky said.

Rensselaer is already active in stem cell research. A number of Rensselaer faculty members, including NYSTEM-funded researchers Robert Linhardt and Deanna Thompson, maintain stem cell research programs within the CBIS. But Monastersky said the new grant will greatly enhance the program.

A key goal of the grant is to encourage upstate researchers to take advantage of the availability of the Rensselaer stem cell facility. Monastersky said that Rensselaer will be working with several key players in the field.

"The idea was to create an upstate center of excellence so we can maximize the research that's going on in New York state," Monastersky said. "These facilities and the associated scientific staff will enhance collaborations with several New York state partners, including the New York Neural Stem Cell Institute, Albany Medical College, and the Ordway Institute."

Scientific colleagues from the University at Albany-SUNY, the University of Rochester Medical School, Northeast Health System, and the Trudeau Institute also will participate in guiding the research efforts with Monastersky.

"Our goal is to become an important location for stem cell research in New York state," Monastersky said.

Stem cell therapies hold promise for treatments of human diseases and traumatic injuries because they can be grown into specialized cells like nerve, muscle, and bone, and could therefore be used to regenerate missing or damaged cells.

Rensselaer plans to work with existing stem cell lines, Monastersky said.

Monastersky said the focus of the research in the CBIS will be the basic science critical to development of stem-cell based therapies for human diseases and traumatic injuries. Growing the cells and controlling their "differentiation" guiding their development into the specialized cell types of the human body are key scientific challenges.

"All of these totipotent cells from the very early embryo are identical, and have the potential to develop into any of the mature cell types of the body," Monastersky said. "To use them, we need to know how to guide the development of cultured embryonic stem cells into these specialized cell types e.g., nerve, muscle, and bone cells."

Space within the existing collection of Research Cores in the CBIS will be created as a dedicated resource for stem cell research, for Rensselaer investigators, and for stem cell researchers from other institutions, particularly across New York state.

"We are excited that this funding will enhance our ongoing efforts to recruit world-class faculty for our faculty Constellation in Tissue Engineering and Regenerative Medicine, which is located in the CBIS," Monastersky said.


Contact: Mary Martialay
Rensselaer Polytechnic Institute

Related biology news :

1. Deadly dose: Rensselaer heparin expert helps uncover source of lethal contamination
2. Trustee makes donation to start new solar energy research center at Rensselaer
3. Rensselaer receives more than $2 million from New York State to fund stem cell research
4. Rensselaer leads effort to replace 1 of the most widely used drugs in American hospitals
5. Rensselaer researchers to send bacteria into orbit aboard space shuttle Atlantis
6. Palm Beach County wants to establish a Max Planck Institute in Florida
7. Midlands Consortium delighted to be chosen to host £1 billion energy institute
8. $22 million gift from Alfred Taubman launches new biomedical research institute
9. 3 Columbia University Medical Center faculty elected to Institute of Medicine
10. Stowers Institutes Xie Lab demonstrates dual intrinsic and extrinsic control of stem cell aging
11. Weizmann Institute scientists discover: A risk distribution law for evolution
Post Your Comments:
(Date:6/9/2016)... control systems is proud to announce the introduction of fingerprint attendance control software, allowing ... are actually signing in, and to even control the opening of doors. ... ... ... Photo - ...
(Date:6/2/2016)... -- The Department of Transport Management (DOTM) of ... US Dollar project, for the , Supply and ... and IT Infrastructure , to Decatur ... of Identity Management Solutions. Numerous renowned international vendors participated in ... was selected for the most compliant and innovative solution. ...
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology: